H Lee Moffitt Cancer & Research Institute
Welcome,         Profile    Billing    Logout  
 23 Trials 
39 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Strosberg, Jonathan
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
ACTION-1, NCT05477576: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
07/25
07/28
CABINET, NCT03375320: Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Hourglass Feb 2020 - Dec 2020 : Data from CABINET trial for advanced NET
Active, not recruiting
3
298
US
Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Carcinoid Tumor, Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Metastatic Pancreatic Neuroendocrine Neoplasm, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Thymic Neuroendocrine Neoplasm, Neuroendocrine Neoplasm, Neuroendocrine Tumor G2, Non-Functioning Pancreatic Neuroendocrine Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Thymic Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Pancreatic Neuroendocrine Neoplasm, Unresectable Thymic Neuroendocrine Neoplasm
08/23
05/25
NCT01253161: Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Completed
2
29
US
Pasireotide Long Acting Release (LAR), SOM 230
H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals, RECORDATI GROUP
Neuroendocrine Tumors, Carcinoid Tumors
10/21
03/23
NCT03290079: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Completed
2
20
US
Pembrolizumab, Keytruda®, Lenvatinib, Lenvima®
H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC
Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer
01/23
05/24
NCT04123262: Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression

Recruiting
2
15
US
Tamoxifen 20 mg
H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
02/23
06/23
HORMONET, NCT03870399: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

Completed
2
23
US, RoW
Tamoxifen
AC Camargo Cancer Center, H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
05/23
05/23
NCT06519097: Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

Recruiting
2
212
US
Vitamin E Delta Tocotrienol, DT3, Placebo
H. Lee Moffitt Cancer Center and Research Institute, American River Nutrition, LLC, National Cancer Institute (NCI)
Neoplasm of Pancreas, IPMN, Pancreatic
07/27
07/29
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Malignant Neoplasm of Unknown Primary, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NCT06553885: Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Not yet recruiting
2
40
US
Enfortumab Vedotin, PADCEV
H. Lee Moffitt Cancer Center and Research Institute, Astellas Pharma Inc
Metastatic Colorectal Cancer, Hepatocellular Carcinoma
09/29
09/29
SWOG S2104, NCT05040360: Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Recruiting
2
141
US
Capecitabine, Ro 09-1978/000, Xeloda, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
SWOG Cancer Research Network, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
03/25
03/25
ALPHAMEDIX02, NCT05153772: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

Active, not recruiting
2
69
US
AlphaMedix, Pb212-octreotide analog
Radiomedix, Inc., Orano Med LLC
Neuroendocrine Tumors
10/26
10/26
NCT06378047: Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Recruiting
1
3
US
Pembrolizumab, Keytruda, Irreversible Electroporation, NanoKnife
H. Lee Moffitt Cancer Center and Research Institute, Angiodynamics, Inc.
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
04/27
04/27
NCT04069299: Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Recruiting
N/A
30
US
68Ga-DOTATATE, NETspot, Positron Emission Tomography (PET) Scan
H. Lee Moffitt Cancer Center and Research Institute, Advanced Accelerator Applications
Neuroendocrine Carcinoma
05/25
05/25
Fleming, Jason B
NCT04955730: NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies

Recruiting
2/3
300
US
Negative Pressure Wound Therapy, PICO
H. Lee Moffitt Cancer Center and Research Institute
Surgical Wound Infection
11/24
11/25
PaTK02, NCT02446093: Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Active, not recruiting
2
54
US, RoW
Aglatimagene besadenovec, CAN-2409, AdV-tk, Chemoradiation, Stereotactic body radiation therapy, Surgery
Candel Therapeutics, Inc., Mayo Clinic
Borderline Resectable Pancreatic Adenocarcinoma
12/25
07/26
NCT05664178: Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

Recruiting
1/2
100
US
Tele-Resistance Training
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI)
Gastrointestinal Cancer
02/25
02/25
NCT05649969: STRONG Program for Cancer Patients

Active, not recruiting
N/A
10
US
Consultations with Moffitt Dietician, Daily Food Intake Diary with Fitbit smartphone application, Questionnaires
H. Lee Moffitt Cancer Center and Research Institute
Gastrointestinal Cancer
11/23
12/24
PuraBond PROOF, NCT05773781: PuraBond® and Pain Following Resection of Oral or Oropharyngeal Mucosal Lesions

Active, not recruiting
N/A
73
Europe
PuraBond
University of Liverpool
Pain, Hemorrhage, Hemostatics, Oropharynx, Oral Cavity
08/24
08/24
STRONG-GEC, NCT05438940: Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients

Active, not recruiting
N/A
23
US
Fitbit Data Collection, Nutrition Counseling, Survey
H. Lee Moffitt Cancer Center and Research Institute
GastroEsophageal Cancer
06/25
06/26
NCT05438927: Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer

Active, not recruiting
N/A
50
US
Fitbit Data Collection, Nutrition Counseling, Fact G Survey, General Anxiety Disorder (GAD)-7, Patient Health Questionnaire (PHQ)-9
H. Lee Moffitt Cancer Center and Research Institute, Canopy Cancer Collective
Pancreatic Cancer
11/24
11/24
NCT05692596: The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Recruiting
N/A
500
US
Data collection
H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome, FAP, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
02/25
02/26
NCT05675059: Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

Recruiting
N/A
80
US
Consultations with Moffitt Dietician, Daily Food Intake Diary with Fitbit Smartphone application, Questionnaires
H. Lee Moffitt Cancer Center and Research Institute, Pancreatic Cancer Action Network
Pancreatic Cancer
12/24
12/24
NCT06112535: Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery

Recruiting
N/A
60
Europe
Versius Surgical System
CMR Surgical Ltd, Liverpool University Hospitals NHS Foundation Trust, Sintesi Research S.r.l.
Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma, Unknown Primary
12/24
02/25
NCT05687188: Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

Recruiting
N/A
125
US
Blood Sample Collection, Tissue Sample Collection, Data Collection, Medical Image Collection
H. Lee Moffitt Cancer Center and Research Institute, United States Department of Defense
Pancreatic Cancer
12/26
12/26
Hodul, Pamela
NCT04955730: NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies

Recruiting
2/3
300
US
Negative Pressure Wound Therapy, PICO
H. Lee Moffitt Cancer Center and Research Institute
Surgical Wound Infection
11/24
11/25
NCT06519097: Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

Recruiting
2
212
US
Vitamin E Delta Tocotrienol, DT3, Placebo
H. Lee Moffitt Cancer Center and Research Institute, American River Nutrition, LLC, National Cancer Institute (NCI)
Neoplasm of Pancreas, IPMN, Pancreatic
07/27
07/29
NCT05664178: Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

Recruiting
1/2
100
US
Tele-Resistance Training
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI)
Gastrointestinal Cancer
02/25
02/25
NCT06323291: Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study

Recruiting
1
20
US
Coaching Sessions
H. Lee Moffitt Cancer Center and Research Institute, Canopy Cancer Collective
Pancreatic Cancer
03/26
03/26
NCT06378047: Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Recruiting
1
3
US
Pembrolizumab, Keytruda, Irreversible Electroporation, NanoKnife
H. Lee Moffitt Cancer Center and Research Institute, Angiodynamics, Inc.
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
04/27
04/27
NCT04091165: Mobile APP Utilization for Enhanced Post-Operative Nutritional Recovery

Completed
N/A
23
US
My Plate Calorie Tracker, mobile application
H. Lee Moffitt Cancer Center and Research Institute
GI Cancer, Nutritional Deficiency
07/20
01/22
NCT06423963: Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Recruiting
N/A
26
US
Physical Activity, Nutrition Counseling, Resistance Training
H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer
02/25
02/26
NCT05438927: Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer

Active, not recruiting
N/A
50
US
Fitbit Data Collection, Nutrition Counseling, Fact G Survey, General Anxiety Disorder (GAD)-7, Patient Health Questionnaire (PHQ)-9
H. Lee Moffitt Cancer Center and Research Institute, Canopy Cancer Collective
Pancreatic Cancer
11/24
11/24
NCT05675059: Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

Recruiting
N/A
80
US
Consultations with Moffitt Dietician, Daily Food Intake Diary with Fitbit Smartphone application, Questionnaires
H. Lee Moffitt Cancer Center and Research Institute, Pancreatic Cancer Action Network
Pancreatic Cancer
12/24
12/24
NCT06050395: The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response

Active, not recruiting
N/A
40
US
Quality fo Life Questionnaire (FHSI), Vioscreen Food Frequency Questionnaire (FFQ), Educational Handouts, NutritionCoaching, Follow-Up Survey, Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire, Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire
H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer
12/24
12/24
STRONG-PCS, NCT06001268: Support Through Remote Observation and Nutrition Guidance Program

Recruiting
N/A
80
US
Fitbit Data Collection, Nutrition Counseling, Survey
H. Lee Moffitt Cancer Center and Research Institute, United States Department of Defense
Pancreatic Cancer
08/27
08/27
Al-Toubah, Taymeyah
NCT04123262: Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression

Recruiting
2
15
US
Tamoxifen 20 mg
H. Lee Moffitt Cancer Center and Research Institute
Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
02/23
06/23
NCT04069299: Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Recruiting
N/A
30
US
68Ga-DOTATATE, NETspot, Positron Emission Tomography (PET) Scan
H. Lee Moffitt Cancer Center and Research Institute, Advanced Accelerator Applications
Neuroendocrine Carcinoma
05/25
05/25
Schneider, Lynn
NCT04069299: Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Recruiting
N/A
30
US
68Ga-DOTATATE, NETspot, Positron Emission Tomography (PET) Scan
H. Lee Moffitt Cancer Center and Research Institute, Advanced Accelerator Applications
Neuroendocrine Carcinoma
05/25
05/25

Download Options